Remicade (infliximab) is a prescription drug that’s used to manage certain autoimmune conditions in adults and some children. The drug is usually given as an intravenous (IV) infusion every 8 weeks.

Maintenance doses of the biologic agent infliximab (Remicade) can be safely administered at a patient's home with a very low rate of adverse events (AEs) and serious AEs, according to research ...

Although use of corticosteroid premedication prior to infliximab infusions is declining, it remains unnecessarily high despite limited benefit and the risk of serious adverse events from ...

ORLANDO – Maintenance doses of the biologic agent infliximab (Remicade) can be safely administered at a patient's home with a very low rate of adverse events (AEs) and serious AEs, a researcher ...

Remicade (infliximab) is a prescription drug that’s used to treat certain autoimmune conditions, such as rheumatoid arthritis. Remicade can cause side effects that range from mild to serious. Examples ...

Therapeutic persistence with infliximab was associated with signifi cantly fewer ulcerative colitis patients requiring hospitalization; once hospitalized, patients with therapeutic persistence had ...

Birmingham, UK - Although infliximab (Remicade, Centocor) was licensed for use in the treatment of ankylosing spondylitis (AS) in Europe nearly 2 years ago, in the UK there has been little experience ...

Infliximab (Remicade, Schering-Plough Ltd) is a tumour necrosis factor alpha (TNF-α) inhibitor and has a UK marketing authorisation for the treatment of moderately to severely active ulcerative ...

Treatment with infliximab, a chimeric monoclonal IgG1 antibody against tumor necrosis factor, can result in the formation of antibodies against infliximab. We evaluated the clinical significance of ...

Adalimumab (Humira, Abbott Laboratories) is a human-sequence monoclonal antibody that binds specifically to TNF and neutralises its biological function by blocking its interaction with cell-surface ...